The findings from a recent study unveiled notable distinctions in bleeding rates between etranacogene dezaparvovec and the standard prophylactic factor IX (FIX) products among individuals diagnosed with hemophilia B.
The results of a new investigation revealed significant differences in bleeding rates between etranacogene dezaparvovec and conventional prophylactic factor IX (FIX) products in patients with hemophilia B.
In the absence of direct comparisons between etranacogene dezaparvovec, a gene therapy for hemophilia B, and FIX products in the phase 3 HOPE-B trial, investigators utilized indirect treatment comparisons (ITC) to evaluate etranacogene dezaparvovec effectiveness against specific FIX therapies, including rIX-FP, rFIXFc, and N9-GP.
The HOPE-B trial yielded promising results regarding the efficacy of etranacogene dezaparvovec. The therapy demonstrated superior performance in reducing bleeds compared with the FIX products over a 24-month period, offering a potentially transformative approach to hemophilia B treatment.
To assess the efficacy of etranacogene dezaparvovec in comparison to other FIX products, investigators leveraged data from multiple phase 3 pivotal trials, including HOPE-B, PROLONG-9FP, B-LONG, and Paradigm 2. Annualized bleeding rates (ABR), spontaneous (AsBR) and joint (AjBR) bleeding rates, percentage of patients with no bleeds, and FIX consumption were analyzed using advanced statistical techniques, such as inverse probability of treatment weighting and matching adjusted indirect comparisons.
The findings of the ITC analysis show significant differences in bleeding rates between etranacogene dezaparvovec and the comparator FIX products. Etranacogene dezaparvovec exhibited remarkably lower bleeding rates compared with rIX-FP, with rate ratios for ABR, AsBR, and AjBR being 0.19 (P < .0001), 0.08 (P < .0001), and 0.09 (P < .0001), respectively.
Similarly, when compared with rFIXFc, the rate ratios for ABR, AsBR, and AjBR were 0.14 (P < .0001), 0.13 (P = .0083), and 0.15 (P = .0111), respectively.
Against N9-GP, etranacogene dezaparvovec demonstrated rate ratios for ABR and AsBR of 0.24 (P = .0231) and 0.13 (P = .0071), respectively.
The therapy also exhibited a significantly higher percentage of patients with no bleeds compared with rIX-FP, with odds ratios of 17.60 (P < .0001) and rFIXFc, 5.65 (P = .0037). Additionally, the gene therapy resulted in substantially lower FIX consumption than all comparators, further emphasizing its efficiency, investigators noted.
One of the study’s strengths was that it utilized data from pivotal phase 3 trials, ensuring the use of high-quality information. Another was its rigorous ITC feasibility assessment, which compared trial designs, eligibility criteria, and outcomes definitions to ensure a robust analysis. Additionally, clinical experts were consulted to identify and prioritize important factors, aiding in minimizing bias during the analysis.
The study authors also acknowledged limitations. The first mentioned was the exclusion criteria, because gene therapy with etranacogene dezaparvovec might not be suitable for specific patients with hemophilia B, such as those with FIX inhibitory antibodies or advanced liver fibrosis. Therefore, the benefits demonstrated in this study were applicable only to individuals meeting specific gene therapy eligibility criteria.
Adjusting for various factors was limited due to sample size constraints and differences in trial designs, according to the study. Differences in baseline characteristics and trial durations could have introduced bias. The investigators also noted incomplete data reporting in some trials and differences in outcome definitions might have influenced the results. The availability of individual patient data for etranacogene dezaparvovec versus summary-level data for rFIXFc and N9-GP posed challenges in ensuring identical study populations for comparison.
However, despite these limitations, the study's comprehensive approach and careful consideration of factors provided valuable insights into the potential advantages of etranacogene dezaparvovec over existing hemophilia B treatments. Further research, particularly in specific patient subsets, is warranted to establish the full scope of gene therapy benefits in diverse hemophilia B populations, according to the study.
“Based on these findings, etranacogene dezaparvovec improves protection against bleeding and largely eliminates FIX consumption for patients with severe or moderately severe hemophilia B (i.e., FIX activity ≤ 2% of the normal value),” investigators wrote.
Reference
Klamroth, R, Bonner, A, Gomez, K, et al. Indirect treatment comparisons of the gene therapy etranacogene dezaparvovec versus extended half-life factor IX therapies for severe or moderately severe haemophilia B. Haemophilia. 2023; 1-12. https://doi.org/10.1111/hae.14882
Coexistence of HIV, Hemophilia May Lead to Increased Presence of Coronary Artery Stenosis
May 8th 2024In patients living with HIV, the cardiovascular risk factors that come with infection may lead to an increased prevalence of coronary artery stenosis, especially in those who also have hemophilia.
Read More
AA Unlikely to Cause Anxiety, Depression but May Be Affected by Mental Illness
May 7th 2024A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a causal link while adding to existing evidence.
Read More
Social Equity, Strong Health Care Systems Can Improve Advanced Breast Cancer Outcomes Globally
May 6th 2024Disparities in health care systems around the world limit access to effective treatments for advanced breast cancer, especially for people in low- and middle-income countries and marginalized communities. Stronger health systems and social education efforts are necessary to improve outcomes for all patients.
Read More
Review: One-Shot Etranacogene Dezaparvovec Represents Game-Changing Gene Therapy for Hemophilia B
May 3rd 2024More than 20 years of gene therapy clinical research have led to etranacogene dezaparvovec’s use in hemophilia B, according to authors of a recent review—and it takes its place in a line of current and potentially many future genomic medicines for a range of diseases.
Read More